Giant cell arteritis is a common systemic vasculitis affecting the elderly, with maximum prevalence in the 7 th decade of age, targeting aortic derived medium and large vessels of the neck and head. Diagnosis is established on a biopsy specimen of the temporal artery wall, through pathological confirmation of panarteritis, typically characterized by mononuclear cell infiltrate, with the 1990 ACR criteria often used in clinical practice.
INTRODUCTION
Giant cell arteritis (GCA) is a type of systemic vasculitis occurring exclusively in the elderly population, mainly affecting the large vessels derived from the aortic arch, with the superficial temporal artery known as a predilect location. Historically, its clinical stigmata are a new onset temporal headache, jaw claudication or ocular manifestations such as amaurosis fugax or diplopia in a patient with raised biological inflammatory markers. Establishing the diagnosis employs the 1990 ACR criteria, while a positive temporal artery biopsy is commonly considered the gold-standard test. Over the last two decades, CDUS of the temporal arteries has been used as an ancillary diagnostic method, recent studies proposing it as an alternative test to the classical ones, with excellent reproducibility and interobserver agreement of the two findings: hypoechoic periluminal ring of the temporal arteriesthe halo sign, and visibility of the artery after transducer-imposed compression.
CASE REPORT
An 83 year old patient was addressed to our clinic for a history of persistent unilateral right headache, prominently more severe in the periauricular area, with associated ipsilateral scalp hyperesthesia. His symptoms were ongoing for the past two months, and had been unresponsive to non-steroidal antiinflammatory medication, opioid antalgics and gabapentin. Regarding his medical history, he had developed right malignant otitis externa two months prior to the first admission in our clinic, and had been subsequently treated in an ENT department with remission of the ear canal exudate. He then underwent repeated neurological consultations precluding a primary headache disorder, while a cerebral CT-scan ruled out an underlying central nervous system cause or mastoiditis. At this point, he had persistent higher values of the ESR (41 mm/h), so he was redirected to the ENT specialist, with suspected recurrence of the ear infection, overruled by the absence of local inflammation signs. He was then prescribed an opioid antalgic and low-dose oral corticosteroid treatment (equivalent of prednisone 5 mg daily), with very limited therapeutic response. One week later the patient presented to our clinic for the first time and upon clinical examination he was afebrile, with no recent weight loss or other constitutional signs, blood pressure was normal, he had palpable peripheral pulse in all limbs, and no cardiac murmurs or pulmonary rales were detected on auscultation.
On neurological examination, he had hyperesthesia and allodynia of the right scalp, in the dermatome of the ophthalmic nerve, and continuous ipsilateral headache with localised increased severity in the periauricular area. Case history was negative for episodic vision loss, diplopia or ocular pain, with no evidence of clinical abnormalities of temporal arteries. He had no pain associated vegetative manifestations, such as hyperlacrimation or nasal discharge, so a trigeminal autonomic cephalalgia seemed improbable, nor did he have photo/phonophobia or nausea, to suggest migraine. He had bilateral severe hypoacusis and no other signs of cranial nerve involvement. Routine blood work revealed mildly elevated biological markers of inflammation (ESR was 48 mm/h, and CRP was 10 mg/dL) and a normal white blood cell count. GCA emerged as a clinical suspicion, therefore a CDUS of the extracranial carotid branches was then performed, showing evidence of compression resistant hypoechoic periluminal halo of the temporal arteries, measuring 0.7 mm bilaterally. This warranted a TAB. With the pathology result pending, we considered a low to medium probability for a positive diagnosis of GCA, given the recent history of ear infection, yet decided to initiate corticosteroid treatment with 0.75 mg/kg/daily prednisone. A week later, the patient returned for re-evaluation, while biopsy results came back negative for inflammatory infiltrate within the vessel wall or subsequent vasculitis-associated lesions. He reported substantial pain relief, albeit with recurrence exclusively in the evening or during the night, presumably once the effect of prednisone wore off. Follow-up CDUS revealed a significantly smaller hypoechoic perivascular ring of the right temporal artery, now measuring 0.3 mm. In this setting, by correlating the presence of bilateral halo of the temporal arteries and its size reduction under glucocorticoid treatment, with aforementioned clinical findings and additional symptom relief, we established the diagnosis of GCA.
Follow up at one month after treatment initiation revealed remission of the headache, therefore we started tapering the corticosteroid medication. In the meantime, he had developed high blood pressure, and he also presented symptoms suggestive of steroid induced myopathy, manifesting as proximal muscle weakness leading to increasing difficulty in movement. One month later, he was still headache-free, but he developed steroid-induced diabetes.
Given the side effects experienced, steroid tapering was continued at a faster rate. He returned to our clinic two months later, now on the equivalent of 10 mg of oral prednisone daily, with features suggestive of rebound: he had intermittent left hemicranial headache and scalp hyperesthesia, and there was ultrasonographic evidence of the right temporal artery halo enlargement, now measuring 1.2 mm (Fig. 1) . There was evidence of systemic inflammation: ESR was 75 mm/h, CRP was 20 mg/dL, with associated mild normochromic normocytic anaemia, hyperferritinemia and reactive thrombocytosis, and no signs of an underlying infection or malignancy on usual screening methods. Consequently, the diagnosis was now confirmed, so the corticosteroid dose was raised to the equivalent of 60 mg of prednisone daily. His symptoms subsequently wore off, and he was later started on methotrexate, as a steroid sparing agent. 
DISCUSSIONS
At baseline, according to the ACR criteria and biopsy findings, this patient did not have giant cell arteritis, but two of the five ACR diagnostic criteria were met, namely the patient's age and new onset headache, with the ESR marginally close to the 50 mm/h limit [1] . Notably, bilateral presence of the halo sign is cited as yielding a specificity of 100% for GCA, when compared to the ACR criteria as reference, showing its supremacy as a diagnostic test over clinical and biological markers classically associated with giant cell arteritis [2] . Among these, jaw claudication ( LR+ = 4.2), physical examination abnormalities of the temporal arteries (LR+ varying from 4.3 to 4.6), diplopia (LR+ = 3.4) and an ESR over 100 mm/h (LR+ = 1.9) are the ones likeliest to predict a positive diagnosis, yet all result in only slight to moderate increases in the probability of disease, varying from 15 to 30%. [3] . The clinical setting did not include any of the features relevant for the biopsy proven diagnosis: the presence of temporal headache holds only an estimated LR+ of 1.5, while any type of headache stands even lower at 1.2 [3] . Since there was no histological confirmation of vasculitis, the diagnosis of giant cell arteritis relied on the highly specific imaging features, meaning the bilateral halo of the temporal arteries [2, 3, 4] with the added finding of the compression sign -visibility of the artery after transducer-imposed compression, suggesting vessel wall inflammation [5] . After the initial clinical assessment, we considered a pre-test probability of 15% for a positive diagnostic of GCA, which resulted in a post-test calculated probability of 88%, based on the LR+ of 43 yielded by the bilateral halo sign [3] . That, in turn impacted our decision to initiate corticosteroid therapy. So, the imaging technique turned to be the key to the diagnosis, otherwise not clearly sustained by initial clinical and biological findings. Several studies also showed a potential benefit of ultrasonographic follow-up in patients exhibiting the halo sign at baseline, with evidence of regression of the wall edema in most cases, once steroid treatment was initiated. [6, 7, 8, 9] . However, there is lack of congruence between the mean time to halo disappearance, ranging from 7 days in one case report [7] to a mean of 11 weeks in a 30 patients cohort study [9] , with both using the 0.3 mm threshold in defining the halo sign. One case report showed a negative halo sign after 2 days of treatment [10] . In our case, halo disappearance (according to the same criterion) was documented 7 days after high dose oral glucocorticoid initiation, preceding complete remission of the headache, a finding similar to the report of De Miguel et al. There is a potential role of halo assessment in order to monitor disease activity, with several study showing its decrease paralleling reduction of the ESR during disease course [9] . The rebound our patient experienced once reaching a low dose of corticosteroid, encompassed raised biological markers of inflammation, recurrence of the headache and augmentation of the right temporal artery halo practically confirmed the diagnosis. It also added to the observational inference that halo monitoring may be useful in asessing arteritic flares. Others even raised the possibility of using CDUS as a method for early detection of relapses [7] . However, establishing a gold standard for comparison remains problematic, with the ideal option of repeated biopsies rendered unethical. Previous researchers looked into the diagnostic value of the halo sing by comparing it to a positive biopsy, resulting in a lower specificity, varying from 81-87% [4, 11, 12] , a practice which excluded all patients that had the disease, but whose biopsies turned out negative due to the segmental nature of the vasculitic lesions (the so-called biopsy-negative GCA). This case suggests the possibility of using the clinical evolution as a reference standard in future studies aiming to determine the diagnostic accuracy of CDUS.
High-dose glucocorticoids remain the cornerstone of the treatment of GCA and currently the only therapeutic option available for the most dreaded complication of the disease, which is sight loss related to anterior ischemic optic neuropathy [13, 14, 15] . However, evidence-based rules regarding initial dose and administration route, treatment duration, or the appropriate manner and parameters to guide the dose tapering, have yet to be approved, so in many cases it all depends on the clinician's judgement and previous experience. [16, 17] . In the absence of high-quality randomized control trials to confirm this, data from several retrospective studies established regimens for initial treatment include doses varying from 20 to 60 mg of oral prednisone, for patients without impending or recent visual symptoms [13] , [14, 18] . It Is generally accepted that once clinical remission is achieved and biological markers of inflammation remain consistently within normal ranges, steroid tapering is adequate, and this is usually accomplished within one to four weeks of treatment [13, 17] . It would be wise to consider halo monitoring as an additional mean in guiding medication tapering, but future trials are needed to confirm its use. 
